I also have to wonder if Cortex will prefer licensing only RD next year and then continue working at maximizing the deals for AD/ADHD, and for the high impacts - which obviously would require additional good trial results and additional time.
Historically Dr. Stoll has always emphasised how the low terms for the deals in the past have hamstrung Cortex - thus I wouldn't be surprised at all if company sentiment still runs towards maximizing the remaining 2 potentially large deals Cortex could make: low impacts AD/ADHD, and high impacts.
It's a very fundamental question and the company's plan for those 2 deals will have a huge impact for both Cortex's future and us investors vis a vis the pps of COR.
The landscape has dramatically changed for Cortex after the IND rejection that killed the ADHD licensing plan that would have brought in a large upfront payment and funded the company for 2-3 years intensive development. So Cortex mgmt has had to reevaluate strategy for the 2 big deals they still have left to make.
It would be really interesting to know which direction they are truly leaning for next year.
Of course this all hinges on how the RD trial turns out, and whether the RD results stay on schedule. Bad RD results, or much of a delay at all, will force either an incredibly dilutive financing or a "backed into a corner" deal for the low impacts and/or the high impacts.
Market Data 
Markets 
AI
